{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:36:50Z","timestamp":1793824610137,"version":"4.6.1"},"reference-count":130,"publisher":"European Respiratory Society (ERS)","issue":"153","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,5,24]]},"published-print":{"date-parts":[[2019,9,30]]},"abstract":"<jats:p>Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines. These medications have been shown to reduce the rate of decline in forced vital capacity among patients with IPF over time and are the only two disease-modulating pharmacological agents approved by regulatory agencies and available for clinical use worldwide. With the evolved standard of care for interstitial lung disease evaluation including routine use of high-resolution computed tomography, fibrotic lung diseases other than IPF are increasingly recognised. In addition, it is becoming evident that genetic and pathophysiological mechanisms as well as disease behaviour in patients manifesting other \u201cnon-IPF progressive fibrotic interstitial lung diseases\u201d (non-IPF-PF) may be similar to those in patients with IPF. Thus, it is biologically plausible that pharmacological agents with antifibrotic properties may be efficacious in non-IPF-PF. Indeed, studies are underway or planned to assess the safety and efficacy of nintedanib or pirfenidone among patients with several non-IPF fibrotic lung diseases. In this review, we briefly summarise the use of pirfenidone and nintedanib in IPF as well as the rationale and potential for use of these medications in non-IPF-PF that are being investigated in ongoing and upcoming clinical trials.<\/jats:p>","DOI":"10.1183\/16000617.0022-2019","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T07:45:10Z","timestamp":1570002310000},"page":"190022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":121,"title":["Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis"],"prefix":"10.1183","volume":"28","author":[{"given":"Bridget F.","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Raghu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"2024102403401865000_28.153.190022.1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2024102403401865000_28.153.190022.2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2024102403401865000_28.153.190022.3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2213-2600(14)70011-6","article-title":"Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102403401865000_28.153.190022.4","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0509PP"},{"key":"2024102403401865000_28.153.190022.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01209-2017"},{"key":"2024102403401865000_28.153.190022.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102403401865000_28.153.190022.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102403401865000_28.153.190022.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102403401865000_28.153.190022.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2024102403401865000_28.153.190022.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2024102403401865000_28.153.190022.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2024102403401865000_28.153.190022.13","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018"},{"key":"2024102403401865000_28.153.190022.14","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?","volume":"66","author":"Herzog","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403401865000_28.153.190022.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.137"},{"key":"2024102403401865000_28.153.190022.16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403401865000_28.153.190022.17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.rmed.2017.03.027","article-title":"High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival","volume":"126","author":"Yunt","year":"2017","journal-title":"Respir Med"},{"key":"2024102403401865000_28.153.190022.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2024102403401865000_28.153.190022.19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181bb2538"},{"key":"2024102403401865000_28.153.190022.20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2214\/AJR.16.17121","article-title":"CT findings, radiologic-pathologic correlation, and imaging predictors of survival for patients with interstitial pneumonia with autoimmune features","volume":"208","author":"Chung","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"2024102403401865000_28.153.190022.21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MCP.0000000000000408","article-title":"Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?)","volume":"23","author":"Kreuter","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"2024102403401865000_28.153.190022.22","doi-asserted-by":"crossref","unstructured":"Richeldi L , Varone F , Bergna M , et\u00a0al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev 2018; 27: 180074.","DOI":"10.1183\/16000617.0074-2018"},{"key":"2024102403401865000_28.153.190022.23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.chest.2017.02.011","article-title":"Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis","volume":"152","author":"Wang","year":"2017","journal-title":"Chest"},{"key":"2024102403401865000_28.153.190022.24","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.4.9805017"},{"key":"2024102403401865000_28.153.190022.25","doi-asserted-by":"crossref","unstructured":"Raghu G , Kinsella M Cytokine effects on extracellular matrix. In: Kelly J , ed. Cytokines in the Lung. New\u00a0York, Marcel Dekker, 1992; pp. 491\u2013543.","DOI":"10.1201\/9781003066927-20"},{"key":"2024102403401865000_28.153.190022.26","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/138.3.703"},{"key":"2024102403401865000_28.153.190022.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00198013"},{"key":"2024102403401865000_28.153.190022.28","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208710"},{"key":"2024102403401865000_28.153.190022.29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"Albera","year":"2016","journal-title":"Eur Respir J"},{"key":"2024102403401865000_28.153.190022.30","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0047-2017"},{"key":"2024102403401865000_28.153.190022.31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00408-016-9912-1","article-title":"First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of","volume":"194","author":"Wuyts","year":"2016","journal-title":"Lung"},{"key":"2024102403401865000_28.153.190022.32","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.8498"},{"key":"2024102403401865000_28.153.190022.33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000487711","article-title":"A real-life multicenter national study on nintedanib in severe idiopathic pulmonary fibrosis","volume":"95","author":"Harari","year":"2018","journal-title":"Respiration"},{"key":"2024102403401865000_28.153.190022.34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12931-019-0977-2","article-title":"Effect of pirfenidone on lung function decline and survival: a 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry","volume":"20","author":"Zurkova","year":"2019","journal-title":"Respir Res"},{"key":"2024102403401865000_28.153.190022.35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.36","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01339-2016"},{"key":"2024102403401865000_28.153.190022.37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1755-1536-3-16","article-title":"The multifaceted role of pirfenidone and its novel targets","volume":"3","author":"Mac\u00edas-Barrag\u00e1n","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2024102403401865000_28.153.190022.39","first-page":"367","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2024102403401865000_28.153.190022.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2007.11.003"},{"key":"2024102403401865000_28.153.190022.41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","article-title":"An open label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration"},{"key":"2024102403401865000_28.153.190022.42","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2024102403401865000_28.153.190022.43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102403401865000_28.153.190022.44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00230-2018"},{"key":"2024102403401865000_28.153.190022.46","first-page":"S191","article-title":"Strategies to manage costs in idiopathic pulmonary fibrosis","volume":"23","author":"Owens","year":"2017","journal-title":"Am J Manag Care"},{"key":"2024102403401865000_28.153.190022.47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","article-title":"Diagnosis and treatment of fibrotic hypersensitivity pneumonitia: where we stand and where we need to go","volume":"196","author":"Salisbury","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.48","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","article-title":"Hypersensitivity pneumonitis: perspectives in diagnosis and management","volume":"196","author":"Vasakova","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.49","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00004914"},{"key":"2024102403401865000_28.153.190022.50","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.6.2019"},{"key":"2024102403401865000_28.153.190022.51","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-201442"},{"key":"2024102403401865000_28.153.190022.52","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"2024102403401865000_28.153.190022.53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2214\/AJR.17.18384","article-title":"CT features of the usual interstitial pneumonia pattern: differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis","volume":"210","author":"Chung","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"2024102403401865000_28.153.190022.54","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2321030174"},{"key":"2024102403401865000_28.153.190022.55","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0444"},{"key":"2024102403401865000_28.153.190022.56","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102403401865000_28.153.190022.57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102403401865000_28.153.190022.58","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00308-2016"},{"key":"2024102403401865000_28.153.190022.59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2213-2600(13)70191-7","article-title":"Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study","volume":"1","author":"Morell","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102403401865000_28.153.190022.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2024102403401865000_28.153.190022.61","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102403401865000_28.153.190022.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6819"},{"key":"2024102403401865000_28.153.190022.63","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0741"},{"key":"2024102403401865000_28.153.190022.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2024102403401865000_28.153.190022.65","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.208223"},{"key":"2024102403401865000_28.153.190022.66","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007068313370"},{"key":"2024102403401865000_28.153.190022.67","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155108"},{"key":"2024102403401865000_28.153.190022.68","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2024102403401865000_28.153.190022.69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2024102403401865000_28.153.190022.70","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200211-1311OC"},{"key":"2024102403401865000_28.153.190022.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500526"},{"key":"2024102403401865000_28.153.190022.72","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201311-1951OC"},{"key":"2024102403401865000_28.153.190022.73","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00200614"},{"key":"2024102403401865000_28.153.190022.74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60551-1"},{"key":"2024102403401865000_28.153.190022.75","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202640"},{"key":"2024102403401865000_28.153.190022.76","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0006PP"},{"key":"2024102403401865000_28.153.190022.77","first-page":"S111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403401865000_28.153.190022.78","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024102403401865000_28.153.190022.79","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0102-2017"},{"key":"2024102403401865000_28.153.190022.80","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024102403401865000_28.153.190022.81","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2223-2"},{"key":"2024102403401865000_28.153.190022.82","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1007\/s00330-016-4697-4","article-title":"Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis","volume":"27","author":"Jacob","year":"2017","journal-title":"Eur Radiol"},{"key":"2024102403401865000_28.153.190022.83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rmed.2017.07.007","article-title":"Unclassifiable-interstitial lung disease: outcome prediction using CT and functional indices","volume":"130","author":"Jacob","year":"2017","journal-title":"Respir Med"},{"key":"2024102403401865000_28.153.190022.84","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.3"},{"key":"2024102403401865000_28.153.190022.85","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","article-title":"Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis","volume":"151","author":"Morisset","year":"2015","journal-title":"Chest"},{"key":"2024102403401865000_28.153.190022.86","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203265"},{"key":"2024102403401865000_28.153.190022.87","first-page":"139","article-title":"Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience","volume":"35","author":"Shibata","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024102403401865000_28.153.190022.88","first-page":"A4394","article-title":"Pirfenidone shows some beneficial effect in patients with chronic hypersensitivity pneumonitis","volume":"191","author":"Buendia-Roldan","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.89","unstructured":"National Institutes of Health Clinical Center. Pirfenidone in the chronic hypersensitivity pneumonitis treatment (Picheon). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02496182 Date last accessed: February 9, 2019. Date last updated: July 14, 2015."},{"key":"2024102403401865000_28.153.190022.90","unstructured":"National Institutes of Health Clinical Center. Study of efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02958917 Date last accessed: February 9, 2019. Date last updated: August 24, 2018."},{"key":"2024102403401865000_28.153.190022.91","unstructured":"National Institutes of Health Clinical Center. A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02597933 Date last accessed: February 9, 2019. Date last updated: December 7, 2018."},{"key":"2024102403401865000_28.153.190022.92","unstructured":"National Institutes of Health Clinical Center. Efficacy and safety of nintedanib in patients with progressive fibrosing interstitial lung disease (PF-ILD) (INBUILD). December 18, 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02999178 Date last accessed: February 9, 2019. Date last updated: May 15, 2019."},{"key":"2024102403401865000_28.153.190022.93","unstructured":"National Institutes of Health Clinical Center. Nintedanib in lung transplant recipients with bronchiolitis obliterans syndrome grade 1-2 (INFINITx-BOS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03283007 Date last accessed: February 10, 2019. Date last updated: April 26, 2018."},{"key":"2024102403401865000_28.153.190022.94","unstructured":"National Institutes of Health Clinical Center. Pirfenidone in progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. July 1, 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02821689 Date last accessed: February 9, 2019. Date last updated: July 1, 2016."},{"key":"2024102403401865000_28.153.190022.95","unstructured":"National Institutes of Health Clinical Center. Scleroderma lung study III \u2013 combining pirfenidone with mycophenolate (SLSIII). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03221257 Date last accessed: February 9, 2019. Date last updated: April 4, 2019."},{"key":"2024102403401865000_28.153.190022.96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) \u2013 a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"Behr","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2024102403401865000_28.153.190022.97","unstructured":"National Institutes of Health Clinical Center. A study of pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03099187 Date last accessed: February 9, 2019. Date last updated: May 29, 2019."},{"key":"2024102403401865000_28.153.190022.98","unstructured":"National Institutes of Health Clinical Center. Pilot study of pirfenidone in pulmonary fibrosis with anti-myeloperoxydase antibodies (PIRFENIVAS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03385668 Date last accessed: February 9, 2019. Date last updated: March 19, 2019."},{"key":"2024102403401865000_28.153.190022.99","unstructured":"National Institutes of Health Clinical Center. Phase II study of pirfenidone in patients with RAILD (TRAIL1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808871 Date last accessed: February 9, 2019. Date last updated: August 23, 2019."},{"key":"2024102403401865000_28.153.190022.100","unstructured":"National Institutes of Health Clinical Center. Pirfenidone for progressive fibrotic sarcoidosis (PirFS). September 28, 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03260556 Date last accessed: February 9, 2019. Date last updated: September 28, 2017."},{"key":"2024102403401865000_28.153.190022.101","unstructured":"National Institutes of Health Clinical Center. European trial of pirfenidone in BOS, a European multi-center study (EPOS). https:\/\/clnicaltrials.gov\/ct2\/show\/NCT02262299 Date last accessed: February 10, 2019. Date last updated: August 31, 2018."},{"key":"2024102403401865000_28.153.190022.102","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024102403401865000_28.153.190022.103","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"issue":"Suppl. 106","key":"2024102403401865000_28.153.190022.104","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403401865000_28.153.190022.105","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130187"},{"key":"2024102403401865000_28.153.190022.106","first-page":"280","article-title":"Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: shared mechanistic and phenotypic traits suggest overlapping disease mechanisms","volume":"67","author":"Paulin","year":"2015","journal-title":"Rev Invest Clin"},{"key":"2024102403401865000_28.153.190022.107","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","article-title":"Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease","volume":"314","author":"Redente","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102403401865000_28.153.190022.108","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0154-4"},{"key":"2024102403401865000_28.153.190022.109","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023"},{"key":"2024102403401865000_28.153.190022.110","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"2024102403401865000_28.153.190022.111","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000289"},{"key":"2024102403401865000_28.153.190022.112","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00150-2015"},{"key":"2024102403401865000_28.153.190022.113","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chest.2017.03.004","article-title":"Idiopathic interstitial pneumonia associated with autoantibodies: a large case series followed over 1 year","volume":"152","author":"Collins","year":"2017","journal-title":"Chest"},{"key":"2024102403401865000_28.153.190022.114","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0139-2017"},{"key":"2024102403401865000_28.153.190022.115","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0074-2018"},{"key":"2024102403401865000_28.153.190022.116","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01565-2015"},{"key":"2024102403401865000_28.153.190022.117","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.rmed.2016.10.017","article-title":"Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients","volume":"123","author":"Ahmad","year":"2017","journal-title":"Respir Med"},{"key":"2024102403401865000_28.153.190022.118","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2024102403401865000_28.153.190022.119","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/resp.12931","article-title":"Unclassifiable interstitial lung diseases: clinical characteristics and survival","volume":"22","author":"Hyldgaard","year":"2017","journal-title":"Respirology"},{"key":"2024102403401865000_28.153.190022.120","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00003414"},{"key":"2024102403401865000_28.153.190022.121","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2018.08.008","article-title":"Sarcoidosis and IPF in the same patient \u2013 a coincidence, an association or a phenotype?","volume":"144S","author":"Collins","year":"2018","journal-title":"Respir Med"},{"key":"2024102403401865000_28.153.190022.122","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker236"},{"key":"2024102403401865000_28.153.190022.123","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00110109"},{"key":"2024102403401865000_28.153.190022.124","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000340"},{"key":"2024102403401865000_28.153.190022.125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0038-1669914","article-title":"Antineutrophil cytoplasmic antibody-associated lung fibrosis","volume":"39","author":"Borie","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102403401865000_28.153.190022.126","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2024102403401865000_28.153.190022.127","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.10.022"},{"key":"2024102403401865000_28.153.190022.128","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107514"},{"key":"2024102403401865000_28.153.190022.129","unstructured":"National Institutes of Health Clinical Center. Nintedanib in patients with bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation (NINBOST2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03805477 Date last accessed: February 10, 2019. Date last updated: March 27, 2019."},{"key":"2024102403401865000_28.153.190022.130","unstructured":"National Institutes of Health Clinical Center. The safety and tolerability of pirfenidone for BOS after HCT (STOP-BOS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03315741 Date last accessed: February 10, 2019. Date last updated: June 17, 2019."}],"updated-by":[{"DOI":"10.1183\/16000617.5022-2019","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000}}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0022-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:01:10Z","timestamp":1740355270000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0022-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":130,"journal-issue":{"issue":"153","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2019,9,30]]}},"alternative-id":["10.1183\/16000617.0022-2019"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0022-2019","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]}}}